worry not. just sell to the market. this is just the warrant rights you entitle for holding on to mother. quickly sell it while it is still available (0.005). later probably worth nothing
i'm a newbie @this counter. Feels interested @ this company's warrant issuance....
Anyways, I think base on my study on Biohldg fundamental, I made a conclusion that this company won't be succumb to GN3 in a near future. The company is improving its pofitabilty...
1. NTA 10.85 sen. 2. NOSH 1.406 bilion.
3. EQUITY Share capital RM 186,014,000 Reserves (RM 39,795,000) Equity attributable to owners of the parent RM 146,219,000 Non-controlling interests RM 3,353,000 TOTAL EQUITY RM 149,572,000
4. Cash and Cash Equivalent: Fixed deposit with licensed bank RM 1,018,000 Cash and bank balances RM 9,597,000
5. Assets: Non-current Assets RM 138,443,000 (Note: Including investment in quoted shares RM 23,532,000) Current Assets RM 56,258,000 TOTAL ASSETS RM 194,701,000
6. Liabilities: Current Liabilities RM 12,385,000 Non-current liabilities RM 32,744,000 TOTAL LIABILITIES RM 45,129,000
7. Last QR result-Net loss (RM2,760,000) Note 1: The Group’s current quarter revenue for the financial period ended 30 September 2023 (“3QFY23”) grew by 61.3% year-on-year (“YoY”) to RM11.7 million, as compared to RM7.3 million in the preceding year’s corresponding quarter (“3QFY22”). The growth was driven by improved performance across all the Group’s segments
Note 2: The Group’s revenue for the 3QFY23 increased by 37.7% to RM11.7 million, against RM8.5 million in the second (2nd) quarter ended 30 June 2023.
Note 3: Meanwhile, turnover for the Group’s supply of health foods to China more than doubled to RM3.0 million in 3QFY23 (2QFY23: RM1.4 million) as deliveries to customers picked up. For our retail pharmacy business, revenue grew by 76.8% to RM5.4 million, from RM3.1 million in 2QFY23, on the back of contributions from newly opened pharmacy outlets.
Important dates to read and digest. For those who want to speculate, can use it as an important information. TAYOR. --------------------- Date for commencement of trading of rights 12 Jan 2024 Date for cessation of trading of rights 19 Jan 2024 Date for announcement of final subscription result and basis of allotment of excess Rights Securities 06 Feb 2024 Last date and time for : Sale of provisional allotment of rights 18 Jan 2024 05:00 PM Transfer of provisional allotment of rights 22 Jan 2024 04:30 PM Acceptance and Payment 29 Jan 2024 05:00 PM Excess share application and payment 29 Jan 2024 05:00 PM Available/Listing Date 14 Feb 2024
Note 3 from latest financial reports: For our retail pharmacy business, revenue grew by 76.8% to RM5.4 million, from RM3.1 million in 2QFY23, on the back of contributions from newly opened pharmacy outlets.
Newly opened pharmacy outlets? Let's dig some info:
1. Constant Pharmacy has been around for about 20 years now. It is a government-linked brand which enjoys support from Bioalpha Holdings Berhad. To date, it has grown to more than 13 outlets mostly around the Klang Valley. Google search returned 15 outlets, and this is for over 20 years? AA pharmacy, Alpro pharmacy, Multicare pharmacy and Health Lane pharmacy which are not well known has at least 50 or more shops in Malaysia.
2. Constant Pharmacy in Shopee has extremely low volume of overall items sold: -- Top item is apple cider vinegar sold for 2900+ -- Second top item is Panadol for 300+ Shopee may not constitute a big part of the sales, but still a very sad number if you look at the overall number of items sold.
3. LinkedIn company size for Constant pharmacy shows: -- 51-200 employees -- 39 associated members (members who’ve listed Constant Pharmacy as their current workplace on their profile.) AA pharmacy, Alpro pharmacy, Multicare pharmacy and Health Lane pharmacy has at least 4 times in terms of associated members, and also at least 200 to >1000 employees.
Note 3 from latest financial reports: Meanwhile, turnover for the Group’s supply of health foods to China more than doubled to RM3.0 million in 3QFY23 (2QFY23: RM1.4 million) as deliveries to customers picked up.
In the China agreement, BIO announced the contract to be worth $$$ per year: The value of supplying health food and nutritional meals supplied is approximately RMB700,000,000 per year (equivalent to RM426,700,000).
In a query from Bursa, BIO replied: Query: The basis and justification in arriving the value of the health food and nutritional meals to be supplied of approximately RMB700,000,000 per year (equivalent to RM426,700,000). Reply: The supply contract value of RMB700,000,000 was offered by GYHX based on their requirements to meet the market consumption (public and private sector) based on its high population and health conscious awareness of the health food and nutritional meals.
The turnover of one quarter in 3QFY23 is 3 million, and yet the estimated supply value is 106 million a quarter?
The Group’s QR3 2023 revenue based on the geographical location of its customers is presented as follows:
Malaysia RM8,633,000 Indonesia RM14,000 China RM3,029,000 Others RM44,000 Total RM11,720,000 Note: Revenue from Malaysia QR3 2023 up 40% from RM5,133,000 in QR3 2022. Revenue from China also up 56% from RM1,943,000 in QR3 2022.
Burnt some here...... For the sake of an experiment on a new counter.. Sorry guys... In facts, the information is still valid.. But this counter is not suitable for me to play... He He He
Look for capital changes in above link ========== Take note of NOSH exceeding 1 BILLION shares due to directors massive fund raising via shares, warrant and PA issuance
Look for capital changes in above link ========== Take note of NOSH exceeding 1 BILLION shares due to directors massive fund raising via shares, warrant and PA issuance
Be careful of directors doing frequent fund raising via shares issuance to PA, ESOS, RI,
================== Continue to monitor quarterly results directors plan for utilisation of company funds directors plan for more fund raising via shares issuance to PP, ESOS or asset acquisition
Newbies don't touch this stock. Had bought this counter during the pandemic times when healthcare theme was in play, speculative rise and fall, while insiders keep dumping their shares. Keep raising funds through RI and losses year after year. Bought only for speculative play.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
VinAlag
8 posts
Posted by VinAlag > 2024-01-12 13:52 | Report Abuse
wait im a bit lost...i didnt subsribe for it...it just appeared in my trading account..will they be back charging for it? im a bit lost sorry